Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Dovish Fed lifts Wall Street stock futures to record high

Thu, 08th Apr 2021 12:57

* S&P stock futures hit record highs

* European shares at record levels

* Crude oil slips after rise in U.S. gasoline stocks

* Fed's Powell to speak at IMF event at 1600 GMT

* Weekly U.S. jobless claims data due at 1230 GMT

* ECB reassures on accommodative monetary policy

By Huw Jones

LONDON, April 8 (Reuters) - Wall Street was poised to notch
a record high on Thursday after reassurance from the Federal
Reserve that its bond-buying support for economic recovery won't
be ending anytime soon.

E-mini futures on the S&P 500 were up 0.33% at 4,083
points, just off a record high of 4,092.75 earlier. Nasdaq
futures gained 0.86%

Minutes of the Fed's last policy meeting, published on
Wednesday, showed members felt the economy was still short of
target and were in no rush to scale back their $120 billion a
month of bond buying.

"As long as that message remains consistent and, more
importantly, unified, that is going to have a bigger and bigger
influence on yields," said Derek Halpenny, head of research for
global markets at MUFG.

"That is what is key in the market at the moment, as rates
appear to have reached some degree of equilibrium, and that is
what is encouraging the equities market performance. I can't
really see anything on the immediate horizon to upset that."

U.S. Treasuries yields were down from their
14-month highs, although analysts said markets will be tested
next week when the U.S. earnings seasons gets underway.

The U.S. weekly jobless claims data is due at 1230 GMT, and
is expected to show the number of Americans filing for new
unemployment benefits dropped in the latest week, a further sign
the economy is recovering from COVID-19.

Fed Chairman Jerome Powell speaks at 1600 GMT at an
International Monetary Fund event and he is likely to reiterate
the dovish outlook.

There was little in the way of corporate news, though shares
in Tesla Inc rose about 1% after President Joe Biden's
administration proposed a $174 billion boost to electric
vehicles.

ECB DOVISH TOO

Stocks in Europe also reached record highs, buoyed by
optimism in Britain over easing lockdown restrictions and
supportive outlooks from the Fed and the European Central Bank.

The European STOXX index of 600 leading companies
rose 0.44%, just off the high of 436.66 points it reached
earlier in the session. London's blue-chip FTSE 100 index
was up 0.4%.

"It's looking good as evaluations in Europe are much lower
than they are in the U.S., so there is potentially more upside.
The line of least resistance for European markets is higher,"
said Michael Hewson, chief market analyst at CMC Markets.

"In terms of economic re-opening, there is enough optimism
built in at the moment to drive markets quite a bit higher from
here, and the Fed has reiterated it's going to remain on hold
for a while," Hewson said.

The ECB said in the account of its March 11 meeting,
published on Thursday, that it was important to provide
reassurance there would be no change in its accommodative
monetary policy for as long as necessary.

In Asia, MSCI's broadest index of Asia-Pacific shares
outside Japan inched up 0.3% in quiet trade.
Japan's Nikkei slipped 0.3%, not helped by news Tokyo's
governor had asked for emergency measures to stem a surge of
COVID-19 infections.

In currencies, the dollar index eased to 92.291 from
its recent five-month high at 93.439.

The euro was steady at $1.1877, after rising as high
as $1.1914 overnight following a surprisingly upbeat survey of
European Union business activity.

In commodity markets, gold was at $1,750 an ounce.

Oil prices fell after official figures showed a big
increase in U.S. gasoline stockpiles, causing concern about
demand for crude weakening in the world's biggest consumer of
the resource at a time when supplies around the world are
rising.

Brent fell 29 cents to $62.87 a barrel. U.S. crude
lost 44 cents to $59.33 per barrel.

(Aditional reporting by Wayne Cole and Chibuike Oguh; editing
by Larry King)

More News
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.